Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hannah E. Landsberg, MSN, MPH, Jacquelyn Turcinovic, B.S., Madison Sullivan, MPH, John H. Connor, Ph.D., Davidson H. Hamer, MD, Judy T. Platt, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	COVID-19 Sequencing Delta variant Variant of concern PCR testing Contact tracing Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:52bd5f1be98c4a7b8d31ec631ce2ec32
record_format	dspace
spelling	oai:doaj.org-article:52bd5f1be98c4a7b8d31ec631ce2ec322021-11-26T04:24:32ZEfficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster1201-971210.1016/j.ijid.2021.10.053https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec322022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221008407https://doaj.org/toc/1201-9712ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant of concern by international authorities. This article reports a cluster of SARS-CoV-2 Delta cases detected in Boston, Massachusetts, in May 2021 involving a recent traveller from India and subsequent transmission to two of three close contacts. All three close contacts experienced the same primary exposure events but differed in vaccination status. The two close contacts that eventually tested positive were unvaccinated. The other close contact had received one dose of the BNT162b (Pfizer-BioNTech) vaccine prior to exposure, and received their second dose 2 days after exposure. This case series illustrates the effectiveness of partial vaccination in blocking transmission of the Delta variant to vaccinated individuals under circumstances where the probability of transmission for unvaccinated individuals is high.Hannah E. Landsberg, MSN, MPHJacquelyn Turcinovic, B.S.Madison Sullivan, MPHJohn H. Connor, Ph.D.Davidson H. Hamer, MDJudy T. Platt, MDElsevierarticleCOVID-19SequencingDelta variantVariant of concernPCR testingContact tracingInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 114, Iss , Pp 62-64 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 Sequencing Delta variant Variant of concern PCR testing Contact tracing Infectious and parasitic diseases RC109-216
spellingShingle	COVID-19 Sequencing Delta variant Variant of concern PCR testing Contact tracing Infectious and parasitic diseases RC109-216 Hannah E. Landsberg, MSN, MPH Jacquelyn Turcinovic, B.S. Madison Sullivan, MPH John H. Connor, Ph.D. Davidson H. Hamer, MD Judy T. Platt, MD Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
description	ABSTRACT: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) sublineage B.1.617.2 or Delta, a variant that began circulating in India and is becoming dominant in the USA, has been responsible for significant morbidity and mortality. In May 2021, the Delta variant was upgraded to a variant of concern by international authorities. This article reports a cluster of SARS-CoV-2 Delta cases detected in Boston, Massachusetts, in May 2021 involving a recent traveller from India and subsequent transmission to two of three close contacts. All three close contacts experienced the same primary exposure events but differed in vaccination status. The two close contacts that eventually tested positive were unvaccinated. The other close contact had received one dose of the BNT162b (Pfizer-BioNTech) vaccine prior to exposure, and received their second dose 2 days after exposure. This case series illustrates the effectiveness of partial vaccination in blocking transmission of the Delta variant to vaccinated individuals under circumstances where the probability of transmission for unvaccinated individuals is high.
format	article
author	Hannah E. Landsberg, MSN, MPH Jacquelyn Turcinovic, B.S. Madison Sullivan, MPH John H. Connor, Ph.D. Davidson H. Hamer, MD Judy T. Platt, MD
author_facet	Hannah E. Landsberg, MSN, MPH Jacquelyn Turcinovic, B.S. Madison Sullivan, MPH John H. Connor, Ph.D. Davidson H. Hamer, MD Judy T. Platt, MD
author_sort	Hannah E. Landsberg, MSN, MPH
title	Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
title_short	Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
title_full	Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
title_fullStr	Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
title_full_unstemmed	Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
title_sort	efficacy of pfizer-biontech in sars-cov-2 delta cluster
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/52bd5f1be98c4a7b8d31ec631ce2ec32
work_keys_str_mv	AT hannahelandsbergmsnmph efficacyofpfizerbiontechinsarscov2deltacluster AT jacquelynturcinovicbs efficacyofpfizerbiontechinsarscov2deltacluster AT madisonsullivanmph efficacyofpfizerbiontechinsarscov2deltacluster AT johnhconnorphd efficacyofpfizerbiontechinsarscov2deltacluster AT davidsonhhamermd efficacyofpfizerbiontechinsarscov2deltacluster AT judytplattmd efficacyofpfizerbiontechinsarscov2deltacluster
_version_	1718409900836519936

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster

Ejemplares similares